TY - JOUR
T1 - Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents
AU - Kumar, Adarsh
AU - Bhagat, Kuber Kumar
AU - Singh, Ankit Kumar
AU - Singh, Harshwardhan
AU - Angre, Tanuja
AU - Verma, Amita
AU - Khalilullah, Habibullah
AU - Jaremko, Mariusz
AU - Emwas, Abdul-Hamid M.
AU - Kumar, Pradeep
N1 - KAUST Repository Item: Exported on 2023-03-06
Acknowledgements: Authors are highly thankful to Central University of Punjab, DST-FIST, India, to infrastructural support for completion of this study. The APC was funded by King Abdullah University of Science and Technology (KAUST), Thuwal, Jeddah, Saudi Arabia.
PY - 2023/2/28
Y1 - 2023/2/28
N2 - Cancer is a major cause of deaths across the globe due to chemoresistance and lack of selective chemotherapy. Pyrido[2,3-d]pyrimidine is an emerging scaffold in medicinal chemistry having a broad spectrum of activities, including antitumor, antibacterial, CNS depressive, anticonvulsant, and antipyretic activities. In this study, we have covered different cancer targets, including tyrosine kinase, extracellular regulated protein kinases – ABL kinase, phosphatidylinositol-3 kinase, mammalian target of rapamycin, p38 mitogen-activated protein kinases, BCR-ABL, dihydrofolate reductase, cyclin-dependent kinase, phosphodiesterase, KRAS and fibroblast growth factor receptors, their signaling pathways, mechanism of action and structure–activity relationship of pyrido[2,3-d]pyrimidine derivatives as inhibitors of the above-mentioned targets. This review will represent the complete medicinal and pharmacological profile of pyrido[2,3-d]pyrimidines as anticancer agents, and will help scientists to design new selective, effective and safe anticancer agents.
AB - Cancer is a major cause of deaths across the globe due to chemoresistance and lack of selective chemotherapy. Pyrido[2,3-d]pyrimidine is an emerging scaffold in medicinal chemistry having a broad spectrum of activities, including antitumor, antibacterial, CNS depressive, anticonvulsant, and antipyretic activities. In this study, we have covered different cancer targets, including tyrosine kinase, extracellular regulated protein kinases – ABL kinase, phosphatidylinositol-3 kinase, mammalian target of rapamycin, p38 mitogen-activated protein kinases, BCR-ABL, dihydrofolate reductase, cyclin-dependent kinase, phosphodiesterase, KRAS and fibroblast growth factor receptors, their signaling pathways, mechanism of action and structure–activity relationship of pyrido[2,3-d]pyrimidine derivatives as inhibitors of the above-mentioned targets. This review will represent the complete medicinal and pharmacological profile of pyrido[2,3-d]pyrimidines as anticancer agents, and will help scientists to design new selective, effective and safe anticancer agents.
UR - http://hdl.handle.net/10754/689968
UR - http://xlink.rsc.org/?DOI=D3RA00056G
U2 - 10.1039/d3ra00056g
DO - 10.1039/d3ra00056g
M3 - Article
C2 - 36865574
SN - 2046-2069
VL - 13
SP - 6872
EP - 6908
JO - RSC Advances
JF - RSC Advances
IS - 10
ER -